Immunoglobulin News and Research

RSS

An overview of spike protein antigen COVID-19 vaccine candidates

A new paper in the journal Reviews in Medical Virology provides a perspective on current vaccine development strategies and tools, which may allow the production of safe and effective vaccines.

22 Feb 2021

Study profiles the nose to predict immune response during COVID-19

SARS-CoV-2 resides in mucous membranes, making it easy to detect viral load in the nasal cavities. An international group of researchers has characterized the immunological and diagnosis characteristics of patients who may have or are confirmed with SARS-CoV-2 infection. The team found a distinct nasal cytokine profile that could help identify patients at risk for high inflammatory responses to SARS-CoV-2 infection.

22 Feb 2021

Llama-derived nanobodies show neutralizing activity against SARS-CoV-2 variants of concern in vitro

A new study reports the development of nanoantibodies (nAbs) – also called or nanobodiesTM or single-domain antibodies – that effectively bind the SARS-CoV-2 spike protein from the ancestral Wuhan variant as well as the recently detected UK and South African variants.

19 Feb 2021

Chicken-derived antibody shows potent neutralizing capacity against SARS-CoV-2 in vitro

Researchers report on a Chicken-derived antibody against SARS-CoV-2, offering preliminary data on a potential therapeutic for COVID-19 warranting further research.

19 Feb 2021

Domestic dogs unlikely to transmit SARS-CoV-2, say researchers

Researchers in Spain and Germany have conducted a study showing that domestic dogs are unlikely to contribute to the transmission and community spread of SARS-CoV-2 – the agent that causes COVID-19.

19 Feb 2021

Clinical trial launched to analyze bovine-derived immunoglobulins for preventing COVID-19 side effects

The Hospital del Mar Medical Research Institute (IMIM), Hospital del Mar, the University of California-Davis and the University of Texas have launched a clinical trial to analyze how useful a food supplement can be for preventing the worst side effects of COVID-19.

18 Feb 2021

SARS-CoV-2 D614G mutation associated with lower antibody binding

The onset of the COVID-19 pandemic has brought about an international effort to uncover the biology of its causative agent, SARS-CoV-2, and to develop effective and safe antivirals to contain and treat the infection. A new study by a team of researchers in France and Sweden discusses one such study, exploring the relative immunogenicity of the three main structural proteins of the virus.

18 Feb 2021

Clonally expanded plasma cell lineages in SARS-CoV-2 produce specific neutralizing antibodies

A new preprint research paper posted to the bioRxiv server provides a greater understanding of the aspect of humoral immunity against the virus – the plasma cells that pour out a flood of specific antibodies targeting various epitopes on the pathogen.

16 Feb 2021

Nanoparticle COVID-19 vaccine stimulates robust and long lasting immunity in primates

In the study, published on the preprint server bioRxiv, the team evaluated the ability of AS03, CpG 1018 formulated in Alum, the TLR-7 agonist adsorbed to Alum (AS37), the squalene-in-water emulsion (O/W), and Alum to boost protective immunity against SARS-CoV-2.

15 Feb 2021

Researchers observe rapid increase of SARS-CoV-2 antibodies in plasma over pandemic's course

Researchers found that neutralizing antibodies against SARS-CoV-2 can increase over time. They observed that samples taken from convalescent plasma in September 2020 would likely have high enough values by July 2021 to protect immunodeficient patients who receive intravenous immunoglobulins as part of their treatment.

15 Feb 2021

Vaccine candidate containing tetanus toxoid potentially protective against SARS-CoV-2

Researchers from Cuba, China, and France have demonstrated the potential of coupling a viral antigen with the tetanus toxoid protein as a vaccination approach to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

14 Feb 2021

Second dose of Pfizer-BioNTech COVID-19 vaccine may not benefit previously infected individuals

Researchers at the NYU Grossman School of Medicine have shown that a second dose of the Pfizer-BioNTech BNT162b2 vaccine may not offer any additional protection against coronavirus disease 2019 (COVID-19) over one dose among individuals previously infected with the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

10 Feb 2021

Polyclonal SARS-CoV-2 antibody shows potent neutralizing activity in vitro

Researchers shows a fully human immunoglobulin (IgG) that potently inhibits SARS-CoV-2 infection.

10 Feb 2021

Study finds low SARS-CoV-2 antibody responses in asymptomatic and mild COVID-19 cases

Researchers at Northwestern University have noted high rates of asymptomatic and mild infection in a large community-based cohort and low levels of anti-SARS-CoV-2 immunoglobulin G antibody (IgG) in the general population of previously exposed people.

10 Feb 2021

Pediatric trial results show rabies treatment is safe and effective in children

A treatment, known as KEDRAB (Rabies Immune Globulin [Human]), currently used in the prevention of rabies has been demonstrated to be safe and effective for patients age 17 and under.

10 Feb 2021

Study reveals new molecular mechanism linked to severe anaphylaxis

Anaphylaxis is a systemic allergic reaction that can affect the skin, the gastrointestinal tract, the respiratory system and the cardiovascular system.

9 Feb 2021

Smell and taste loss symptoms associated with robust SARS-CoV-2 antibody response in new study

Researchers in Italy report a correlation between the loss of smell and taste and an observed persistence or rise in antibody levels at five months after infection.

9 Feb 2021

Vaccinated mothers may pass on SARS-CoV-2 antibodies to newborns

A new study describes the first case of anti-SARS-CoV-2 antibodies detected in the cord blood of an infant born to a mother immunized with the first dose of an mRNA COVID-19 vaccine three weeks earlier.

9 Feb 2021

Orthodox Jewish in UK disproportionately impacted by COVID-19

Researchers have conducted a study showing an extremely high prevalence of severe acute respiratory coronavirus disease 2 (SARS-CoV-2) within a strictly Orthodox Jewish community in the UK.

7 Feb 2021

Alpaca nanobodies neutralize SARS-CoV-2 in vitro

A new preprint research paper posted to the bioRxiv server reports the development of highly effective neutralizing nanobodies targeting the viral receptor-binding domain (RBD), thus disrupting its engagement with the host cell angiotensin-converting enzyme 2 (ACE2) receptor.

4 Feb 2021

Immunoglobulin News and Research

An overview of spike protein antigen COVID-19 vaccine candidates

Study profiles the nose to predict immune response during COVID-19

Llama-derived nanobodies show neutralizing activity against SARS-CoV-2 variants of concern in vitro

Chicken-derived antibody shows potent neutralizing capacity against SARS-CoV-2 in vitro

Domestic dogs unlikely to transmit SARS-CoV-2, say researchers

Clinical trial launched to analyze bovine-derived immunoglobulins for preventing COVID-19 side effects

SARS-CoV-2 D614G mutation associated with lower antibody binding

Clonally expanded plasma cell lineages in SARS-CoV-2 produce specific neutralizing antibodies

Nanoparticle COVID-19 vaccine stimulates robust and long lasting immunity in primates

Researchers observe rapid increase of SARS-CoV-2 antibodies in plasma over pandemic's course

Vaccine candidate containing tetanus toxoid potentially protective against SARS-CoV-2

Second dose of Pfizer-BioNTech COVID-19 vaccine may not benefit previously infected individuals

Polyclonal SARS-CoV-2 antibody shows potent neutralizing activity in vitro

Study finds low SARS-CoV-2 antibody responses in asymptomatic and mild COVID-19 cases

Pediatric trial results show rabies treatment is safe and effective in children

Study reveals new molecular mechanism linked to severe anaphylaxis

Smell and taste loss symptoms associated with robust SARS-CoV-2 antibody response in new study

Vaccinated mothers may pass on SARS-CoV-2 antibodies to newborns

Orthodox Jewish in UK disproportionately impacted by COVID-19

Alpaca nanobodies neutralize SARS-CoV-2 in vitro

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News